As SOX2 was assumed to be a significant marker to evaluate the progression of prostate cancer (29), the treatment with metabolites from Halobacteriumsalinarum IBRC M10715 could prevent the progression of human prostate cancer. This evidence concerns the gene SOX2 and prostate carcinoma.